AREVA Med Inaugurates Second Lead-212 Production Facility

Print
| Source: AREVA Med
photo-release

Harry LaRosiliere.jpg

Harry LaRosiliere.jpg

Harry LaRosiliere, mayor of Plano; Patrick Bourdet, AREVA Med CEO photo credit: Jim Herndon

PLANO, Texas, April 13, 2016 (GLOBE NEWSWIRE) -- AREVA Med has launched operations at its second high-purity lead-212 (212Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic Distribution and Purification Unit), this facility was officially opened today in the presence of local elected officials, AREVA Med Scientific Advisory Committee, as well as AREVA Group and AREVA Med executives and teams from both the U.S. and France.

A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bccb050d-dfc0-46c3-9964-a31bc2f553f4

Thanks to its unique characteristics, lead-212 is used in targeted alpha therapy (TAT), in an increasing number of promising and innovative studies to target cancer cells, while limiting the impact on nearby healthy cells.

In a centralized modular plant, the DDPU will hold all AREVA Med’s U.S. activities and those of its subsidiary Macrocyclics, the global leader in the design and manufacturing of chelating agents for nuclear medicine. With brand new equipment, this state-of-the-art facility is a unique opportunity for AREVA Med to expand the range and increase the quality of products and services for its American partners and customers. Thanks to this increased production capacities, AREVA Med will accelerate the development of innovative Targeted Alpha Therapies using lead-212 to combat cancer.

Harry LaRosiliere, the mayor of Plano, declared: “It is always a great day when we can welcome to the City of Plano a U.S. Headquarters and international company such as AREVA Med, which does invaluable work in the field of cancer research. We look forward to their success and future expansion as they continue to develop innovative cancer therapies.”

Patrick Bourdet, AREVA Med’s CEO added: “Our new modular and unique U.S. plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent.”

More information at www.arevamed.com, @AREVAmed

More about AREVA Med

AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new therapies to fight cancer.  AREVA Med has developed a unique process to extract lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT), a novel approach which targets and destroys cancer cells, while limiting the impact on nearby healthy cells.  AREVA Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform.

Press Contacts

AREVA Med
Alison Tise
(301) 841-1673
Alison.Tise@areva.com
@AREVAmed